Literature DB >> 36110371

Monomerization of Homodimeric Trefoil Factor 3 (TFF3) by an Aminonitrile Compound Inhibits TFF3-Dependent Cancer Cell Survival.

Vijay Pandey1, Xi Zhang2, Han-Ming Poh3, Baocheng Wang1, Dukanya Dukanya4, Lan Ma1,2, Zhinan Yin5,6, Andreas Bender7, Ganga Periyasamy8, Tao Zhu9,10, Kanchugarakoppal S Rangappa4, Basappa Basappa4, Peter E Lobie1,2,3.   

Abstract

Trefoil factor 3 (TFF3) is a secreted protein with an established oncogenic function and a highly significant association with clinical progression of various human malignancies. Herein, a novel small molecule that specifically targets TFF3 homodimeric functions was identified. Utilizing the concept of reversible covalent interaction, 2-amino-4-(4-(6-fluoro-5-methylpyridin-3-yl)phenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carbonitrile (AMPC) was identified as a molecule that interacted with TFF3. AMPC monomerized the cellular and secreted TFF3 homodimer at the cysteine (Cys)57-Cys57 residue with subsequent more rapid degradation of the generated TFF3 monomers. Hence, AMPC treatment also resulted in cellular depletion of TFF3 with consequent decreased cell viability in various human carcinoma-derived TFF3 expressing cell lines, including estrogen receptor positive (ER+) mammary carcinoma (MC). AMPC treatment of TFF3 expressing ER+ MC cells significantly suppressed total cell number in a dose-dependent manner. Consistently, exposure of TFF3 expressing ER+ MC cells to AMPC decreased soft agar colony formation, foci formation, and growth in suspension culture and inhibited growth of preformed colonies in 3D Matrigel. AMPC increased apoptosis in TFF3 expressing ER+ MC cells associated with decreased activity of EGFR, p38, STAT3, AKT, and ERK, decreased protein levels of CCND1, CCNE1, BCL2, and BCL-XL, and increased protein levels of TP53, CDKN1A, CASP7, and CASP9. siRNA-mediated depletion of TFF3 expression in ER+ MC cells efficiently abrogated AMPC-stimulated loss of cell viability and CASPASE 3/7 activities. Furthermore, in mice bearing ER+ MC cell-generated xenografts, AMPC treatment significantly impeded xenograft growth. Hence, AMPC exemplifies a novel mechanism by which small molecule drugs may inhibit a dimeric oncogenic protein and provides a strategy to impede TFF3-dependent cancer progression.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 36110371      PMCID: PMC9469493          DOI: 10.1021/acsptsci.2c00044

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  60 in total

1.  Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.

Authors:  Ming-Liang You; Yi-Jun Chen; Qing-Yun Chong; Ming-Ming Wu; Vijay Pandey; Ru-Mei Chen; Liang Liu; Lan Ma; Zheng-Sheng Wu; Tao Zhu; Peter E Lobie
Journal:  Oncotarget       Date:  2017-06-13

2.  Trefoil factor 3 (TFF3) enhances the oncogenic characteristics of prostate carcinoma cells and reduces sensitivity to ionising radiation.

Authors:  Omesha Perera; Angharad Evans; Mikhail Pertziger; Christa MacDonald; Helen Chen; Dong-Xu Liu; Peter E Lobie; Jo K Perry
Journal:  Cancer Lett       Date:  2015-03-03       Impact factor: 8.679

3.  Luminal and parenteral TFF2 and TFF3 dimer and monomer in two models of experimental colitis in the rat.

Authors:  Steen Seier Poulsen; Hannelouise Kissow; Kristine Hare; Bolette Hartmann; Lars Thim
Journal:  Regul Pept       Date:  2005-03-30

4.  TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer.

Authors:  Felicity E B May; Bruce R Westley
Journal:  Endocr Relat Cancer       Date:  2015-04-21       Impact factor: 5.678

5.  Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma.

Authors:  Vijay Pandey; Zheng-Sheng Wu; Min Zhang; Rui Li; Jian Zhang; Tao Zhu; Peter E Lobie
Journal:  Breast Cancer Res       Date:  2014-09-30       Impact factor: 6.466

6.  Trefoil factor 3 as a novel biomarker to distinguish between adenocarcinoma and squamous cell carcinoma.

Authors:  Xiao-Nan Wang; Shu-Jing Wang; Vijay Pandey; Ping Chen; Qing Li; Zheng-Sheng Wu; Qiang Wu; Peter E Lobie
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

Review 7.  Pathological and therapeutic roles of bioactive peptide trefoil factor 3 in diverse diseases: recent progress and perspective.

Authors:  Yiqi Yang; Ziyang Lin; Quanyou Lin; Weijian Bei; Jiao Guo
Journal:  Cell Death Dis       Date:  2022-01-17       Impact factor: 8.469

8.  CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression.

Authors:  Hong-Yong Cui; Shi-Jie Wang; Fei Song; Xu Cheng; Gang Nan; Yu Zhao; Mei-Rui Qian; Xi Chen; Jia-Yue Li; Fen-Ling Liu; Yu-Meng Zhu; Ruo-Fei Tian; Bin Wang; Bin Wu; Yang Zhang; Xiu-Xuan Sun; Ting Guo; Xiang-Min Yang; Hai Zhang; Ling Li; Jing Xu; Hui-Jie Bian; Jian-Li Jiang; Zhi-Nan Chen
Journal:  Signal Transduct Target Ther       Date:  2021-07-14

9.  A variant form of the human deleted in malignant brain tumor 1 (DMBT1) gene shows increased expression in inflammatory bowel diseases and interacts with dimeric trefoil factor 3 (TFF3).

Authors:  Jens Madsen; Grith Lykke Sorensen; Ole Nielsen; Ida Tornøe; Lars Thim; Claus Fenger; Jan Mollenhauer; Uffe Holmskov
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

10.  Activation of signaling receptors: do ligands bind to receptor monomer, dimer, or both?

Authors:  Xiaodong Pang; Huan-Xiang Zhou
Journal:  BMC Biophys       Date:  2013-06-03       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.